Ischaemia versus bleeding: the art of clinical decision-making

The Lancet

Volumn 373, Issue 9665, 2009, Pages 695-696

  Stone, Gregg W ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PRASUGREL;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; CORONARY ARTERY DISEASE; DRUG EFFICACY; HEART INFARCTION; HEART MUSCLE REPERFUSION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION; STENT THROMBOSIS; UNITED STATES;

EID: 60649093738     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60413-X     Document Type: Note

References (15)

1. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2008 update. Circulation 117 (2008) e25-e146
2. Keeley E.C., Boura J.A., and Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361 (2003) 13-20
3. Stone G.W. Angioplasty strategies in ST-segment-elevation myocardial infarction: part I: primary percutaneous coronary intervention. Circulation 118 (2008) 538-551
4. Fox K., Steg P.G., Eagle K.A., et al., for the GRACE Investigators. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 297 (2007) 1892-1900
5. Mehta S.R., Yusuf S., Peters R.J., et al., for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
6. Sabatine M.S., Cannon C.P., Gibson C.M., et al., for the Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294 (2005) 1224-1232
7. Hochholzer W., Trenk D., Frundi D., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111 (2005) 2560-2564
8. Price M.J., Endemann S., Gollapudi R.R., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29 (2008) 992-1000
9. 12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 29 (2008) 21-30
10. Wiviott S.D., Trenk D., Frelinger A.L., et al., for the PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116 (2007) 2923-2932
11. Eikelboom J.W., Mehta S.R., Anand S.S., et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114 (2006) 774-782
12. Stone G.W., Witzenbichler B., Guagliumi G., et al., HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358 (2008) 2218-2230
13. Montalescot G., Wiviott S.D., Braunwald E., et al., for the TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373 (2009) 723-731
14. Wiviott S.D., Braunwald E., McCabe C.H., et al., for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
15. Wiviott S.D., Braunwald E., McCabe C.H., et al., for the TRITON-TIMI 38 Investigators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 371 (2008) 1353-1363